Vanguard Group’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-221,968
| Closed | -$881K | – | 4348 |
|
|
2025
Q3 | $881K | Sell |
221,968
-2,236
| -1% | -$15.2K | ﹤0.01% | 3821 |
|
|
2025
Q2 | $2.69M | Buy |
224,204
+37,097
| +20% | +$460K | ﹤0.01% | 3434 |
|
|
2025
Q1 | $2.58M | Hold |
187,107
| – | – | ﹤0.01% | 3402 |
|
|
2024
Q4 | $2.67M | Sell |
187,107
-2,225
| -1% | -$36.6K | ﹤0.01% | 3480 |
|
|
2024
Q3 | $3.61M | Hold |
189,332
| – | – | ﹤0.01% | 3386 |
|
|
2024
Q2 | $3.69M | Buy |
189,332
+23,279
| +14% | +$450K | ﹤0.01% | 3379 |
|
|
2024
Q1 | $3.81M | Buy |
166,053
+20,965
| +14% | +$452K | ﹤0.01% | 3398 |
|
|
2023
Q4 | $2.55M | Buy |
145,088
+629
| +0.4% | +$8.97K | ﹤0.01% | 3515 |
|
|
2023
Q3 | $1.88M | Hold |
144,459
| – | – | ﹤0.01% | 3607 |
|
|
2023
Q2 | $2.43M | Hold |
144,459
| – | – | ﹤0.01% | 3591 |
|
|
2023
Q1 | $2.25M | Hold |
144,459
| – | – | ﹤0.01% | 3629 |
|
|
2022
Q4 | $2.43M | Buy |
144,459
+81
| +0.1% | +$1.46K | ﹤0.01% | 3596 |
|
|
2022
Q3 | $2.45M | Hold |
144,378
| – | – | ﹤0.01% | 3670 |
|
|
2022
Q2 | $3.18M | Hold |
144,378
| – | – | ﹤0.01% | 3599 |
|
|
2022
Q1 | $4.96M | Sell |
144,378
-632
| -0.4% | -$18.9K | ﹤0.01% | 3536 |
|
|
2021
Q4 | $5.98M | Sell |
145,010
-201
| -0.1% | -$13K | ﹤0.01% | 3511 |
|
|
2021
Q3 | $13.1M | Buy |
145,211
+4,805
| +3% | +$424K | ﹤0.01% | 3093 |
|
|
2021
Q2 | $10.3M | Buy |
140,406
+25,237
| +22% | +$1.17M | ﹤0.01% | 3186 |
|
|
2021
Q1 | $4.27M | Buy |
115,169
+2,453
| +2% | +$123K | ﹤0.01% | 3610 |
|
|
2020
Q4 | $4.63M | Buy |
112,716
+3,205
| +3% | +$83.1K | ﹤0.01% | 3394 |
|
|
2020
Q3 | $2.53M | Buy |
109,511
+3,371
| +3% | +$87.1K | ﹤0.01% | 3419 |
|
|
2020
Q2 | $2.99M | Sell |
106,140
-2,890
| -3% | -$85.1K | ﹤0.01% | 3315 |
|
|
2020
Q1 | $2.78M | Buy |
109,030
+38,337
| +54% | +$1.42M | ﹤0.01% | 3206 |
|
|
2019
Q4 | $3.08M | Buy |
70,693
+1,715
| +2% | +$36K | ﹤0.01% | 3329 |
|
|
2019
Q3 | $652K | Buy |
68,978
+7,346
| +12% | +$105K | ﹤0.01% | 3756 |
|
|
2019
Q2 | $899K | Buy |
61,632
+24,712
| +67% | +$441K | ﹤0.01% | 3700 |
|
|
2019
Q1 | $764K | Sell |
36,920
-387
| -1% | -$7.68K | ﹤0.01% | 3693 |
|
|
2018
Q4 | $598K | Sell |
37,307
-46,404
| -55% | -$2.18M | ﹤0.01% | 3699 |
|
|
2018
Q3 | $7.72M | Buy |
83,711
+1,812
| +2% | +$215K | ﹤0.01% | 3052 |
|
|
2018
Q2 | $13.1M | Buy |
81,899
+5,318
| +7% | +$897K | ﹤0.01% | 2767 |
|
|
2018
Q1 | $12.3M | Buy |
76,581
+25,100
| +49% | +$3.06M | ﹤0.01% | 2728 |
|
|
2017
Q4 | $5.41M | Buy |
51,481
+3,464
| +7% | +$372K | ﹤0.01% | 3101 |
|
|
2017
Q3 | $6.29M | Buy |
48,017
+1,247
| +3% | +$152K | ﹤0.01% | 3020 |
|
|
2017
Q2 | $6.39M | Buy |
46,770
+4,699
| +11% | +$564K | ﹤0.01% | 2994 |
|
|
2017
Q1 | $5.01M | Buy |
42,071
+3,044
| +8% | +$359K | ﹤0.01% | 3051 |
|
|
2016
Q4 | $5.23M | Buy |
39,027
+16,912
| +76% | +$4.25M | ﹤0.01% | 3045 |
|
|
2016
Q3 | $5.76M | Buy |
+22,115
| New | +$2.71M | ﹤0.01% | 2937 |
|
Other funds holding CLSD
Vanguard Group's CLSD Position: Q4 2025 in Review
Vanguard Group sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 221,968 shares — an estimated $881K sold.
Vanguard Group first reported a position in CLSD in Q3 2016 and held it in 37 quarters. The position peaked at $13.1M in Q2 2018. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- Vanguard Group reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- Vanguard Group sold 221,968 Clearside Biomedical shares in Q4 2025, an estimated $881K.
- Vanguard Group first reported a position in Clearside Biomedical in Q3 2016 and held it in 37 quarters.
- Vanguard Group's Clearside Biomedical position peaked at $13.1M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.